LUMOS PHARMA INC (LUMO) Stock Price, Quote, News and Overview
NASDAQ:LUMO - Nasdaq - US55028X1090 - Common Stock - Currency: USD
LUMO Quote, Performance and Key Statistics
4.34
0 (0%)
The current stock price of LUMO is 4.34 USD. In the past month the price decreased by -0.46%. In the past year, price increased by 52.28%.
LUMO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About LUMO
Company Profile
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2011-11-11. The firm is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
Company Info
LUMOS PHARMA INC
4200 Marathon Blvd., Suite 200
Austin TEXAS 78756 US
CEO: Richard J. Hawkins
Employees: 33
Company Website: https://lumos-pharma.com/
Investor Relations: http://investors.linkp.com/
Phone: 15122152630
LUMOS PHARMA INC / LUMO FAQ
What is the stock price of LUMOS PHARMA INC today?
The current stock price of LUMO is 4.34 USD.
What is the ticker symbol for LUMOS PHARMA INC stock?
The exchange symbol of LUMOS PHARMA INC is LUMO and it is listed on the Nasdaq exchange.
On which exchange is LUMO stock listed?
LUMO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LUMOS PHARMA INC stock?
10 analysts have analysed LUMO and the average price target is 9.88 USD. This implies a price increase of 127.68% is expected in the next year compared to the current price of 4.34. Check the LUMOS PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LUMOS PHARMA INC worth?
LUMOS PHARMA INC (LUMO) has a market capitalization of 37.54M USD. This makes LUMO a Nano Cap stock.
How many employees does LUMOS PHARMA INC have?
LUMOS PHARMA INC (LUMO) currently has 33 employees.
What are the support and resistance levels for LUMOS PHARMA INC (LUMO) stock?
LUMOS PHARMA INC (LUMO) has a support level at 4.33 and a resistance level at 4.38. Check the full technical report for a detailed analysis of LUMO support and resistance levels.
Is LUMOS PHARMA INC (LUMO) expected to grow?
The Revenue of LUMOS PHARMA INC (LUMO) is expected to grow by 385.58% in the next year. Check the estimates tab for more information on the LUMO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LUMOS PHARMA INC (LUMO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LUMO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LUMO, evaluating the profitability, health, valuation and growth aspects
- LUMOS PHARMA INC (LUMO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LUMOS PHARMA INC (LUMO) Sales and EPS estimates to see what analysts future expectations are.
- LUMOS PHARMA INC (LUMO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LUMOS PHARMA INC (LUMO) Insider and Institutional Ownership to learn about the owners and their transactions.
- LUMOS PHARMA INC (LUMO) Stock Chart to make your own analysis
- LUMOS PHARMA INC (LUMO) Latest news and press-releases to stay up to date.
Does LUMOS PHARMA INC (LUMO) stock pay dividends?
LUMO does not pay a dividend.
What is the Price/Earnings (PE) ratio of LUMOS PHARMA INC (LUMO)?
LUMOS PHARMA INC (LUMO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.29).
LUMO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to LUMO. When comparing the yearly performance of all stocks, LUMO is one of the better performing stocks in the market, outperforming 89.62% of all stocks.
LUMO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LUMO. LUMO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
LUMO Financial Highlights
Over the last trailing twelve months LUMO reported a non-GAAP Earnings per Share(EPS) of -4.29. The EPS decreased by -6.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -199.97% | ||
| ROE | -710.54% | ||
| Debt/Equity | 0 |
LUMO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to LUMO. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 8.71% and a revenue growth 385.58% for LUMO